Search results
Results From The WOW.Com Content Network
CEO, Sanofi. Term. September 2019-. Predecessor. Olivier Brandicourt. Children. 3. Paul Hudson (born 14 October 1967) [2] is a British businessman, and the chief executive (CEO) of Sanofi, the world's fifth largest pharmaceutical company by prescription drug sales. [3]
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers ...
Genzyme. Genzyme was an American biotechnology company based in Cambridge, Massachusetts. Since its acquisition in 2011, Genzyme (also known as Genzyme Transgenics Corp or GTC Biotherapeutics [2]) has been a fully owned subsidiary of Sanofi. In 2010, Genzyme was the world's third-largest biotechnology company, employing more than 11,000 people ...
Biotech company Dendreon (NAS: DNDN) and French pharma giant Sanofi (NYS: SNY) announced layoffs earlier this week. What do these staff reductions signify for the companies and investors? Let's ...
By Ludwig Burger and Anirudh Saligrama. (Reuters) -Sanofi vaunted 12 drugs in development with the potential to make more than $1 billion in annual sales, but failed to reverse a recent plunge in ...
May 31, 2024 at 7:50 AM. (Reuters) -Sanofi and partner Regeneron Pharmaceuticals have secured the European regulator's backing for use of Dupixent in patients with a chronic lung disease even as ...
The following are list of bioCSL flu vaccine brands: [31] Trivalent. Afluria, also marketed as Enzira, Fluvax, and Nilgrip in various different markets. Agrippal, also marketed as Begripal, Fluazur, Sandovac, Agriflu, and Chiroflu in various different markets. Fluad, [32] [1] also marketed as Chiromas in Spain.
Senior management. As of 2008, David Brennan was paid US$1,574,144 for his role as chief executive officer. On 26 April 2012, it was announced that Brennan was to retire in early June of that year. In August 2012, Pascal Soriot was named CEO of AstraZeneca.